Every S-3 that IN8bio, Inc. (INAB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow INAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INAB filings page.
IN8bio, Inc. filed Pre-Effective Amendment No. 1 to its Form S-3 shelf registration to update disclosures and file an updated auditor consent. The prospectus covers the offer and sale, from time to time, of up to $200,000,000 of common stock, preferred stock, debt securities, warrants, rights and units.
The shelf permits offerings in one or more combinations and will be supplemented by prospectus supplements that set specific terms, pricing and distribution methods. The company’s common stock trades on the Nasdaq Capital Market under the symbol INAB (last reported sale $1.49 per share on May 15, 2026). The prospectus states net proceeds are intended for working capital and general corporate purposes, and discloses an aggregate market value of common stock held by non-affiliates of $17,631,022 (based on 8,815,511 non-affiliate shares at $2.00 per share on March 20, 2026).
IN8bio, Inc. has filed a resale registration covering up to 14,384,052 shares of common stock previously issued or issuable to investors in a December 2025 private placement. The shares consist of 4,931,375 PIPE Shares and 9,452,677 Pre-Funded Warrant Shares underlying outstanding pre-funded warrants.
The company is not selling any shares under this prospectus and will receive no proceeds from sales by the selling stockholders. IN8bio previously received approximately $18.6 million in net proceeds from the initial closing of the private placement, where PIPE Shares were sold at $1.38 per share and Pre-Funded Warrants at $1.3799 each.
The Pre-Funded Warrants are exercisable immediately at an exercise price of $0.0001 per share, subject to a beneficial ownership cap of up to 19.99% per holder. The purchase agreement also allows, subject to data and share-price conditions or waivers, a potential second closing of up to 14,579,706 additional shares or pre-funded warrants at the same purchase price.
IN8bio, Inc. filed a Form S-3 shelf registration to offer up to $200,000,000 of securities, including common stock, preferred stock, debt securities, warrants, rights and units, to be sold from time to time at terms set in future prospectus supplements.
Sales may be made directly, through agents, or via underwriters, including at-the-market offerings, block trades, and privately negotiated transactions. Net proceeds from primary sales by the company are intended for working capital and general corporate purposes, as described in future supplements.
The company’s common stock trades on Nasdaq as “INAB.” The last reported sale price was $1.63 per share on November 5, 2025. Public float was $10.4 million as of November 7, 2025 (based on 4,218,313 non‑affiliate shares at $2.46 on October 7, 2025), and the filing notes the I.B.6 limitation that primary sales under this shelf cannot exceed one‑third of public float while it remains below $75.0 million. IN8bio is an emerging growth company and a smaller reporting company.